e-Therapeutics plc: Appointment of Chief Executive Officer
06 April 2017 - 9:00PM
Business Wire
e-Therapeutics plc
(“e-Therapeutics” or the “Company”)
e-Therapeutics plc (AIM: ETX), the drug discovery company,
announces that further to the Company’s announcement on 9 January
2017, Dr. Raymond Barlow has today assumed his position as Chief
Executive Officer.
Dr. Barlow, aged 48, was previously Executive Director of
Corporate Development at Amgen Inc. based in Switzerland. Dr.
Barlow brings to e-Therapeutics broad experience of drug discovery,
development and commercialization, acquired through regional and
global roles in the biotech and pharmaceutical sector. His previous
responsibilities have included scientific, business and corporate
roles with AstraZeneca, Crucell NV and Johnson and Johnson.
All information announced by the Company on 9 January 2017
pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM
Rules for Companies remains true and accurate.
Ray Barlow, CEO of e-Therapeutics, said:
"e-Therapeutics is at the forefront of a new wave of science and
has created a unique, computational-based drug discovery platform.
This platform uses a range of truly cutting-edge technologies,
including artificial intelligence.
"I am convinced of the value in the platform and our
differentiated approach to drug discovery, which should allow us
and potential partners to more efficiently discover more effective
drug treatments.
"My near-term aim is to ensure that our resources are
appropriately focused on activities that are of the greatest
commercial potential to support our ambition of creating value for
our shareholders. As part of this process, I am looking forward to
engaging with our key stakeholders as well as subsequently
positioning and promoting the Company to an industry which needs
the assets and solutions we can provide."
Background Information on Dr Raymond Barlow
Having completed a BSc in Chemistry from Leeds University in
1990, Dr. Barlow moved to the University of Manchester, from where
he gained a PhD in Chemistry in 1994. He then spent a year at
McGill University, Montreal as a post doctoral Fellow before
entering the pharmaceutical industry as a senior scientist with
Zeneca in Pharmaceutical R&D’s Technology Access and Strategic
Alliances team, of which he later became Team Leader in 1998.
Following the merger with Astra, he became a Global Manager in
the Discovery and Development function, in-licensing technologies
and working on the development of a range of molecules, including
those in oncology, cardiovascular, respiratory and inflammatory
disease areas.
Upon completion of a year as a Senior Business Analyst he was
appointed Director of Corporate Development, reporting into
AstraZeneca’s London HQ. In this role he was involved in a number
of transactions and was part of the team responsible for shaping
AstraZeneca’s strategy with the Board, including its move into
biologics. During this period he graduated from Manchester Business
School with an MBA and in 2004 he stepped out of the BD function
into a Regional commercial leadership role in Brussels covering 14
countries in CEE and Russia.
After 10 years with AstraZeneca , Ray moved into the biotech
sector working in senior business development roles for
Microscience Limited and Emergent Solutions Inc (EBS: NASDAQ).
During this period Ray out-licensed a portfolio of Meningitis B
assets (invented at Imperial College) to Sanofi and was involved
with the team that successfully listed EBS on NASDAQ.
Ray then spent 5 years running his own business (BD solutions
Limited) focused upon aiding clients on corporate development and
commercialisation projects. During this period he was CEO of
Asterion Ltd, delivering research deals with Genzyme and Ipsen. In
2010 he joined Crucell NV and was instrumental in the sale of the
business to Johnson & Johnson for whom he worked on a wide
range of infectious disease and vaccine deals, before joining Amgen
in 2012. At Amgen he has also completed numerous deals including
immuno-oncology deals with Boehringer Ingelheim and Genenta,
international commercial deals with GSK and Mitsubishi Tanabe as
well as playing a key part in the acquisition of Onyx
Pharmaceuticals and Dezima Pharma BV.
About e-Therapeutics plc
e-Therapeutics plc (“e-Therapeutics” or “the Company”) is a drug
discovery company with a unique and proprietary in silico discovery
platform based on the application of network science to the
modelling and analysis of cellular processes and leveraging public
and proprietary chemical biology and “multi-omics” data.
The Company is applying its computational platform to the
discovery of new drug candidates for which it can secure robust
intellectual property (IP) rights. The therapeutic focus of the
Company’s discovery activity is in areas of complex disease with
unmet medical need, including immuno-oncology.
The platform is highly productive and, in new discovery
projects, it consistently generates hits in phenotypic screens that
have been progressed into potent, selective, novel drug-like
molecules of multiple chemotypes.
Significant numbers of active molecules can be identified from
screens of modest size, providing gains in both cost and time and
enabling the use of more physiological assays thereby increasing
the likelihood that candidates arising from the approach will
translate into clinically efficacious drugs.
A picture of the new CEO is available on request.
It is based in Oxford, UK. For more information, visit
www.etherapeutics.co.uk.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170406005565/en/
e-Therapeutics plcIain Ross, ChairmanSteve Medlicott,
Finance DirectorTel: +44 (0)1993 883
125www.etherapeutics.co.ukorNumis Securities LimitedMichael
Meade / Freddie Barnfield (Corporate Finance)James Black (Corporate
Broking)Tel: +44 (0) 207 260 1000www.numis.comorInstinctif
PartnersMelanie Toyne Sewell / Alex Shaw / Deborah BellTel: +44
(0) 207 457 2020Email: e-therapeutics@instinctif.com
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024